Company Monitoring Page for UCB-Pharma

latest headlines for company on cafepharma

UCB's bimekizumab finally back on the FDA's review list after May rejection
Fierce Pharma
Wed, 12/28/22 - 08:40 pm
Tags:
UCB Pharma, psoriasis, bimekizumab, FDA
Praxis ends year on high with $100M biobucks UCB deal for epilepsy medicine
Fierce Biotech
Wed, 12/14/22 - 07:40 pm
Tags:
Praxis, UCB Pharma, epilepsy, PRAX-020
UCB lowers 2022 profit expectations amid Ukraine war, rising costs
Fierce Pharma
Mon, 06/27/22 - 10:09 am
Tags:
UCB Pharma, Ukraine, Russia, generics
UCB’s FDA setback delays competition in U.S. with blockbuster J&J psoriasis drug
MedCity News
Sun, 05/15/22 - 11:12 pm
Tags:
UCB Pharma, bimekizumab, psoriasis, FDA, JNJ
UCB takes on Jazz in severe epilepsy with new Fintepla approval
Pharmaforum
Mon, 03/28/22 - 10:06 am
Tags:
UCB Pharma, FDA, Fintepla, Lennox-Gastaut Syndrome, Jazz Pharma, Epidiolex
AbbVie bets $130M on UCB spinout, bagging early-phase Alzheimer's and depression prospect
Fierce Biotech
Tue, 03/1/22 - 10:42 am
Tags:
AbbVie, M&A, Neuroscience, Syndesi Therapeutics, UCB Pharma, Alzheimer's disease, depression
Watch out, AstraZeneca: UCB uncorks late-stage success for $2.1B Soliris rival
Endpoints
Fri, 02/4/22 - 11:11 am
Tags:
UCB Pharma, clinical trials, myasthenia gravis, AstraZeneca, Soliris, zilucoplan
Controversial opioid Zohydro ER pulled from the market
Endpoints
Thu, 02/3/22 - 12:00 am
Tags:
UCB Pharma, epilepsy, Zogenix, Zohydro ER
UCB to buy Zogenix for nearly $2B in 'first step' for M&A in 2022
BioPharma Dive
Wed, 01/19/22 - 11:12 am
Tags:
UCB Pharma, Zogenix, Fintepla, Dravet syndrome
UCB chases after Argenx with FcRN drug for myasthenia gravis
Pharmaforum
Mon, 12/13/21 - 10:48 am
Tags:
UCB Pharma, anti-FcRn, myasthenia gravis, rozanolixizumab
UCB Signs Up To $1.5 Bln Deal With Novartis To Co-develop Two Parkinson's Disease Drugs
NASDAQ
Thu, 12/2/21 - 10:39 am
Tags:
Novartis, UCB Pharma, drug development, Parkinson's Disease
UCB to restrict 340B discounts to hospitals using community pharmacies
Beckers Hospital Review
Wed, 11/24/21 - 10:19 am
Tags:
UCB Pharma, 340B, hopsitals, drug discounts
AbbVie, Janssen, Novartis, Pfizer and UCB to jointly advance 'digital' endpoint for atopic dermatitis
Endpoints
Tue, 11/2/21 - 10:48 am
Tags:
atopic dermatitis, eczema, nocturnal scratch, digital endpoint, AbbVie, Janssen, JNJ, Novartis, Pfizer, UCB Pharma, digital pharma
UCB licenses AI tech for spinal fracture detection to ImageBiopsy
Pharmaforum
Thu, 10/21/21 - 10:43 am
Tags:
UCB Pharma, ImageBiopsy Lab, artificial intelligence, spinal fractures, diagnostics
Go or no go? UCB bids to make a mark in psoriasis
EP Vantage
Mon, 10/4/21 - 10:35 am
Tags:
UCB Pharma, Bimzelx, psoriasis
From Pfizer to Argenx: A look at potential blockbusters awaiting FDA decisions this year
Fierce Pharma
Mon, 09/13/21 - 11:38 pm
Tags:
FDA, Pfizer, Argenx, UCB Pharma, Roche, efgartigimod, bimekizumab, faricimab, abrocitinib
FDA approves expanded indication for UCB’s Briviact to treat pediatric patients
Pharmaceutical Business Review
Tue, 08/31/21 - 10:57 am
Tags:
UCB Pharma, FDA, partial onset seizures, pediatric, brivaracetam
The big approvals still on the cards for 2021
EP Vantage
Thu, 06/17/21 - 11:00 am
Tags:
FDA, drug approvals, Argenx, Novartis, AstraZeneca, Astellas, UCB Pharma, Ascendis Pharma, ChemoCentryx, Axsome Therapeutics
Clarivate Drugs to Watch Report Highlights Four Likely Blockbusters Among Drugs Launching in 2021
PR Newswire
Tue, 03/9/21 - 10:45 am
Tags:
Clarivate, Biogen, Eisai, aducanumab, UCB Pharma, bimekizumab, Relugolix, Pfizer, Takeda, Myovant, vericiguat, Bayer, Merck
UCB taps Microsoft to accelerate drug discovery, clinical trials
Fierce Biotech
Wed, 02/24/21 - 11:13 am
Tags:
UCB Pharma, Microsoft, drug development, drug discovery, artificial intelligence

Pages

last 30 twitter posts

current feelings about your job

Please rate how you feel about your job this moment. 1 = "I hate my job" and 7 = "I love my job"
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Fill in the blank.